Oradin® Tablet: Each tablet contains Loratadine USP 10 mg.
Oradin FT®: Each orally dispersible tablet contains Loratadine USP 10 mg.
Oradin® Suspension: Each 5 ml contains Loratadine USP 5 mg.
Oradin® is a preparation of loratadine. Loratadine is a long acting tricyclic antihistamine with selective peripheral H1-receptor antagonistic activity and no central sedative or anticholinergic effect.
Tablet Adults and children over 6 years of age: 1 tablet (10 mg) once daily. Children 2-5 years: 1/2 tablet (5 mg) once daily. Below 2 years of age: Safety and efficacy of loratadine has not been established.
Orally dispersible tablet Adults and children over 6 years of age:1 Orally dispersible tablet (10 mg) once daily.
Suspension Adults and children over 6 years of age: 10 mL or 2 teaspoonful (10 mg) of suspension once daily. Children of 2-5 years: 5 mL or 1 teaspoonful (5 mg) of suspension once daily. Below 2 years of age: Safety and efficacy of loratadine has not been established.
When administered concurrently with alcohol, loratadine has no potentiating effects as measured by psychomotor performance studies. Erythromycin, ketoconazole, cimetidine and amprenavir may increase plasma concentration of loratadine.
Overdosage:
In the event of overdose, treatment which should be started immediately is symptomatic and supportive. The patient should be induced to vomit, even if emesis has occurred spontaneously, but not in the patients with impaired consciousness. Administration of activated charcoal as a slurry with water may be attempted following emesis. If vomiting is unsuccessful or contraindicated, gastric lavage should be performed.
There is no experience of the use of loratadine in human pregnancy, hence it should not be used during pregnancy. Loratadine is excreted in breast milk, so it should not be administered to lactating mother.
Suspension: Store in a dry place, at a temperature of 2°C - 25°C. Tablet: Store between 2°C - 30°C, protect from excessive moisture. Keep out of reach of children.